Zelebrudomide

Overview

Zelebrudomide is an orally active BTK -targeting PROTAC degrader, with DC 50 values of 4.5 nM and 31 nM against wild-type BTK and BTK C481S mutant, respectively. Zelebrudomide recruits the cereblon E3 ubiquitin ligase complex to mediate the degradation of BTK . Zelebrudomide also acts as a molecular glue to bind the cereblon E3 ubiquitin ligase complex, mediating the degradation of IKZF1 and IKZF3 . Zelebrudomide can be used in the research of B-cell malignancies. (Pink: Btk ligand ( HY-168302 ); Blue: Cereblon ligand ( HY-W087383 ); Black: linker ( HY-168348 )).

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > Btk

Product Information

• Catalog No.: HY-153220
• CAS No.: 2416131-46-7
• Molecular Formula: C39H45N9O5
• Molecular Weight: 719.83
• Purity: 98.71%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Availability: In-stock

Source

Original product source